GP5 and cancer: A recent study advanced suggestions for how best to operationalize GP5 as an outcome in cancer trials, which included the approach taken in the current study [dichotomizing GP5 response as moderate to high bother (“Somewhat”/“Quite a bit”/“Very much” vs. low bother (“Not at all”/“A little bit”)] [39], but future studies should examine other ways to use GP5 in comparisons of treatment arms.